After HCC chemotherapy with sorafenib, CXCR4 was suppressed and this avoided the formation of an immunosuppressive TME, suppressed cancer proliferation and diminished invasion of tumor cells to lung. The gene discussed is CXCR4; the disease is hepatocellular carcinoma.